Circulating miRNA biomaker signatures

Patent metadata

Field	Value
Publication number	US-9708643-B2
Application number	US-201213526463-A
Country	US
Kind code	B2
Filing date	Jun 18, 2012
Priority date	Jun 17, 2011
Publication date	Jul 18, 2017
Grant date	Jul 18, 2017

Abstract

Methods for diagnosis and surveillance of complex multi-factorial disorders such as cancer by screening of easily accessible biomarkers are disclosed. Highly stable cell free Circulating Nucleic Acids (CNA) present as both RNA and DNA species have been discovered in the blood and plasma of humans. Correlations between tumor-associated genomic/epigenetic/transcriptional changes and alterations in CNA levels are strong predictors of the utility of this biomarker class as clinical indicators. Methods for using microRNAs (miRNAs) representing a class of naturally occurring small non-coding RNAs of 19-25 nt as markers that can associate their specific expression profiles with cancer development are disclosed. Methods for isolating plasma fractions for the study of miRNA biomarkers and for measurement of circulating miRNA levels are disclosed.

First claim

What is claimed is:

1. A method for analyzing circulating miRNAs within a sample of blood comprising segregating the circulating miRNAs from cell-associated miRNAs by: (a) spinning the sample of blood to separate it into a cloudy supernatant fraction of plasma, a white blood cell fraction and a red blood cell fraction; (b) removing cell-associated RNAs from the cloudy supernatant fraction by spinning the cloudy supernatant fraction to separate it into a first supernatant primarily including cell-free circulating miRNAs and a first pellet enriched in cell-associated miRNAs; (c) optionally spinning the first supernatant to separate it into a second supernatant primarily including cell-free circulating miRNAs and a second pellet enriched in cell-associated miRNAs; (d) extracting total RNA from either the first supernatant, if step (c) has not been performed, or the second supernatant if step (c) has been performed, wherein the resulting total RNA is enriched in circulating miRNAs as compared to
the starting blood sample, wherein the spin of step (a) is at about 1700 g for 10 minutes and the spin of step (b) is at about 2000 g for 10 minutes and the spin of step (c) is at about 12000 g for 10 minutes;
analyzing the total RNA for circulating miRNA content; and
extracting out interfering signals from contaminant cells in the total RNA, wherein the extracting is performed by a computer upon data comprising the interfering signals from the contaminant cells and signals from the circulating miRNA content, wherein the extracting comprises background subtraction based on GC content of anti-genomic probes.

2. The method of claim 1 wherein the step of analyzing is hybridizing the total RNA to an array comprising probes complementary to miRNA.

3. The method of claim 1 wherein the step of analyzing is qPCR of the total RNA to determine circulating miRNA content.

4. The method of claim 1 wherein the step of analyzing is sequencing of the total RNA to determine circulating miRNA content.

5. The method of claim 1 wherein a stabilizer is added before the total RNA is extracted.

6. The method of claim 5 wherein the stabilizer comprises linear acrylamide.

7. The method of claim 5 wherein the stabilizer comprises a non-human RNA supplement, and wherein the non-human RNA supplement is yeast RNA.

8. The method of claim 5 wherein the stabilizer comprises Trizol-LS.

9. The method of claim 1 , wherein the extracting further comprises:
detecting intensities for the interfering signals and intensities for the signals from the circulating miRNA content by the computer; and
filtering out data for the detected intensities for the interfering signals by the computer.

10. The method of claim 1 , wherein the extracting further comprises at least one of, data transformation, quantile normalization, and median summarization of the data comprising the interfering signals from the contaminant cells and the signals from the circulating miRNA content.

Assignees

• Duttagupta Radharani
• Jones Keith W
• Jiang Rong
• Getts Robert C
• Gollub Jeremy N
• Affymetrix Inc
• Genisphere Llc

Inventors

• Duttagupta Radharani
• Jones Keith W
• Jiang Rong
• Getts Robert C
• Gollub Jeremy N

Classifications

• C12Q2600/158

  Expression markers · CPC title

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/178

  miRNA, siRNA or ncRNA · CPC title

• C12Q1/6879

  for sex determination · CPC title

• C12Q1/6806 Primary

  Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence) · CPC title